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Introduction
Seborrheic dermatitis (SD), a common skin disorder that typically presents as erythematous plaques or patches and The study design is summarized in Figure 1 . Inclusion criteria were clinical diagnosis of SD made by a dermatologist, moderate to severe SD (Seborrheic Dermatitis Area Severity Index [SDASI] =4 plus: ≥3 anatomical sites involved and/or recurrent SD and/or disease unresponsive to conventional topical therapy) and age ≥18 years. Exclusion criteria included the following: any concomitant skin disease (e.g. acne, rosacea, contact dermatitis) or HIV+/AIDS, recent use of antiseborrheic treatment (2 weeks for topical and 4 weeks for systemic therapy), history of allergy to azoles, renal, liver or cardiac disease, patients using drugs interacting with itraconazole (e.g., cyclosporine, isoniazide, omeprazole, warfarin, statins), and pregnant/lactating women. Both itraconazole supported by the positive correlation between yeast density on the skin and the severity of SD and a high efficacy of antifungal agents in the treatment of this disorder [1, 2, 3] .
While SD rarely causes serious complications, it almost always leads to marked aesthetic deterioration and psychological distress due to its chronic and relapsing nature.
Despite high frequency of SD, surprisingly, only few studies have examined the effect of SD on Quality of Life (QoL) [4] [5] [6] .
Although the topical treatment of SD with corticosteroids or antifungals is effective, there is a high risk of relapse and poor patient compliance [7] , and therefore in some cases it is necessary to resort to systemic antifungals, especially in severe disease. Various oral antifungals have been used to control SD with variable success rates. Among them, itraconazole was the most frequently reported oral treatment particularly for severe SD [8] , but therapeutic efficacy was evaluated only by clinical signs and symptoms in previous studies [7, [9] [10] [11] .
Assessing QoL can help in providing patients better service, by acknowledging their real needs and interfering with treatment decisions. Because QoL is a very important aspect in health and no study exists in the literature which assess the effect of treatment on QoL in SD patients, this randomized controlled trial was set up to determine the impact of oral itraconazole on QoL in patients with moderate to severe SD. Statistical analysis was performed using IBM SPSS software. The difference in SDASI, symptom severity and DLQI scores before and after therapy was compared by using paired t-test. Comparisons of mean age, disease duration, number of relapses and BMI between itraconazole and placebo groups and placebo were in capsule form and identical in appearance and were delivered to patients by a third person recruited for this purpose. The study investigator and patients were blind to intervention, and that was maintained until patients completed their last follow up visit.
The QoL was assessed at the start and end of the study by a standard Dermatological Life Quality Index (DLQI) questionnaire (Persian version) filled by patients, which consisted of 10 questions each referring to the previous week.
Each question was scored from 3 (very much) to 0 (not relevant or not at all). The maximum possible score was 30. A questionnaire including the patient's basic profile was filled in the first visit for assessing other secondary outcomes like effect of age, sex, education level, disease duration, number of relapses and body mass index (BMI) on QoL. SDASI was used to determine the disease severity. This scoring system was modified from Psoriasis Area Severity Index (PASI) and the Comert et al study [12] that had already been used in a previous study by Ghodsi et al [13] .
The treatment was administered in two different phases.
In the first phase (initial treatment), topical 1% hydrocorti- 
Discussion
In our study, we showed that quality of life is significantly improved by systemic itraconazole in moderate to severe SD patients. One of the important findings of our study was that patients in the itraconazole group had experienced a 73.36% reduction in DLQI after four months' treatment, compared with 29.16% in the placebo group, and this effect of itraconazole on severe SD (mean DLQI before 6.72 and after 1.79)
is comparable to systemic isotretinoin in acne patients (mean DLQI before=6.7, after=2.8) [14] .
were performed using unpaired t-test. The Pearson correlation was used to assess the link between DLQI and other secondary parameters. P-value<0.05 was considered significant.
Results
Sixty-eight patients who met study criteria were randomly assigned to itraconazole and placebo groups. Eleven patients were lost to follow up. Consequently, 57 patients completed the study and were included in the analysis (Figure 1 ). The main characteristics of patients at baseline and at the end of study are summarized in Table 1 . The mean DLQI score in our study was 5.88±4.30. Although DLQI scores decreased The mean DLQI score in our study was similar to Harlow et al (mean DLQI: 5.9, n=20) [15] but lower than Szepietowski et al (mean 6.92±5.34) [4] . The difference could be explained by the different regional and social backgrounds and disease severity level in these studies. There is marked impairment of QoL in patients with more severe disease, with a greater effect observed in women and in young patients (age subgroup: 26-35 years) with higher educational level (master and PhD level), and this is almost parallel to previous studies [4] [5] . Interestingly, in our study, disease duration and number of relapses had no effect on QoL. Here, adaptations of the patients to the nature of their disease and coping more efficiently with the disease and therapies over a certain period of time may have had effect. The most common site involved in our study was the scalp, but QoL impairment was higher significantly in facial disease. As the appearance plays important role in the society, a patient with a red and flaky face may feel more embarrassed.
The assessment of the impact on quality of life in patients with skin diseases is important for clinical management. It is essential to detect patients at a higher risk of experiencing a worse quality of life in order to treat him/her in a more integrated way. To our knowledge, this trial was the first using a randomized, placebo-controlled design that investigated the effect of itraconazole on the quality of life in moderate to severe SD patients.
Therapeutic efficacy of itraconazole has already been studied in many previous clinical trials [7, [9] [10] [11] 13] . Although study designs and measurement scales were different, the results regarding effect of itraconazole were almost similar in these studies, and this fact shows the marked efficacy of itraconazole in the treatment of severe SD.
Our study met with several limitations. First, no fungal culture was performed and therefore clinical outcome could not be correlated directly to Malassezia colonization. Second, the power of the study is limited by the monocentric design and small sample size of our study, therefore, a larger, multicentric study is warranted to evaluate the therapeutic effect of itraconazole or other newer therapies for SD patients.
Third, the short period of follow up; a longer study period would have been beneficial. Fourth, it is well known that SD may worsen or improve due to many factors such as seasonal variation, host immunity, and host mood status; these factors might have changed the clinical condition in some patients.
Fifth, although the effect of topical therapy declined mainly after two weeks, it might have affected partly over the final result of clinical picture and DLQI.
Conclusions
SD can significantly reduce QoL particularly in severe disease and facial involvement. Pulse therapy with itraconazole can
